$3.89
4.29%
Nasdaq, Mon, Oct 05 2026.
ISIN
US30234E1047
Symbol
EYEN

Eyenovia, Inc. Stock price

$3.89
+0.59 17.88% 1M
+0.59 17.88% 6M
+0.33 9.27% YTD
-6.50 62.56% 1Y
-123.31 96.94% 3Y
-448.11 99.14% 5Y
-789.71 99.51% 10Y
-789.71 99.51% 20Y
Nasdaq, Closing price Mon, Oct 05 2026
+0.16 4.29%
ISIN
US30234E1047
Symbol
EYEN

Is Eyenovia, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
- | -
P/B
-
Financial Health
Equity Ratio
-357.1%
Return on Equity
380.4%
ROCE
-
ROIC
-
Debt/Equity
-
Financials
Revenue | estimate
- | $408.0k
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow | ex SBC
- | -
Growth
Revenue | estimate
- | 580.0%
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
-
FCF per Share
-
Short interest
4.0%
Employees
14
Rev per Employee
$0.0

Eyenovia, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Eyenovia, Inc. forecast:

5x Hold
63%
3x Sell
38%

Analyst Opinions

8 Analysts have issued a Eyenovia, Inc. forecast:

Hold
63%
Sell
38%

Financial data from Eyenovia, Inc.

Mar '25
+/-
%
0.07 0.07
600% 600%
100%
- Direct Costs 3.72 3.72
37,100% 37,100%
5,314%
-3.66 -3.66
-
-5,229%
- Selling and Administrative Expenses 13 13
2% 2%
18,671%
- Research and Development Expense 9.92 9.92
32% 32%
14,171%
-30 -30
1% 1%
-42,157%
- Depreciation and Amortization 0.78 0.78
136% 136%
1,114%
EBIT (Operating Income) EBIT -30 -30
0% 0%
-43,277%
Net Profit -42 -42
31% 31%
-60,543%

In millions USD.

Don't miss a Thing! We will send you all news about Eyenovia, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.

Head office United States
CEO Mr. Rowe
Employees 14
Founded 2014
Website eyenovia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today